Small, 3D-printed devices, designed to be implanted directly under the skin, could allow people with type 1 diabetes to ...

A global research team, led by Wake Forest University’s Dr. Quentin Perrier, has successfully 3D-printed functioning human ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

The once-weekly insulin analog lowered A1c as effectively as once-daily formulations in three new trials in type 2 diabetes.

Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from US pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed ...

The quick uptake of the interchangeable long-acting insulin product was seen across the board in all three pharmacy dispensing channels: Retail: increase of 20,270 prescriptions (P =0.03) ...

Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood.

Of the roughly 38 million in the U.S. with diabetes, 8.4 million use either a rapid-acting or long-acting insulin, or both, the FDA said.

“Approximately 8.4 million Americans rely on insulin therapy, either rapid-acting and/or long-acting, to manage diabetes. Insulin, a hormone made by the pancreas, helps glucose get into a person ...

Approximately 8.4 million Americans rely on insulin therapy, either rapid-acting and/or long-acting, to manage diabetes. Insulin, a hormone made by the pancreas, helps glucose get into a person's ...